EA202091753A1 - Прогностический биомаркер терапии опухоль-инфильтрующими лимфоцитами и его применение - Google Patents
Прогностический биомаркер терапии опухоль-инфильтрующими лимфоцитами и его применениеInfo
- Publication number
- EA202091753A1 EA202091753A1 EA202091753A EA202091753A EA202091753A1 EA 202091753 A1 EA202091753 A1 EA 202091753A1 EA 202091753 A EA202091753 A EA 202091753A EA 202091753 A EA202091753 A EA 202091753A EA 202091753 A1 EA202091753 A1 EA 202091753A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- patients
- biomarker
- tumor
- application
- infilting
- Prior art date
Links
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 210000004698 lymphocyte Anatomy 0.000 title 1
- 239000000092 prognostic biomarker Substances 0.000 title 1
- 102100029215 Signaling lymphocytic activation molecule Human genes 0.000 abstract 6
- 239000000090 biomarker Substances 0.000 abstract 3
- 230000014509 gene expression Effects 0.000 abstract 3
- 108010074687 Signaling Lymphocytic Activation Molecule Family Member 1 Proteins 0.000 abstract 2
- 238000011467 adoptive cell therapy Methods 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000001802 infusion Methods 0.000 abstract 1
- 238000002955 isolation Methods 0.000 abstract 1
- 230000002018 overexpression Effects 0.000 abstract 1
- 238000013517 stratification Methods 0.000 abstract 1
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/65—MicroRNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Developmental Biology & Embryology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Настоящее изобретение касается биомаркера, полезного в адоптивной клеточной терапии. Рассматриваемым биомаркером является CD150, иначе называемый SLAM или SLAMF1. В настоящей заявке авторы демонстрируют, что экспрессия CD150 на инфузионных продуктах из опухоль-инфильтрующих лимфоцитов коррелирует с частотой ответа, наблюдаемой у этих пациентов. Высокая экспрессия CD150 выявляется у пациентов, которые проявляют полный ответ, а низкая экспрессия выявляется у пациентов, которые не отвечают на терапию. Изобретение относится к применению биомаркера для прогнозирования частоты ответа или стратификации пациентов для лечения. Изобретение также охватывает использование этого рецептора в схемах адоптивной клеточной терапии в целом, включая сверхэкспрессию рецептора в популяциях Т-клеток или выделение клеток, экспрессирующих CD150, в целях повышения эффективности.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1801067.8A GB201801067D0 (en) | 2018-01-23 | 2018-01-23 | Biomarkers predictive of tumour infiltrating lymphocyte therapy and uses thereof |
| PCT/GB2019/050188 WO2019145711A1 (en) | 2018-01-23 | 2019-01-23 | Biomarker predictive of tumour infiltrating lymphocyte therapy and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202091753A1 true EA202091753A1 (ru) | 2020-09-23 |
Family
ID=61283558
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202091753A EA202091753A1 (ru) | 2018-01-23 | 2019-01-23 | Прогностический биомаркер терапии опухоль-инфильтрующими лимфоцитами и его применение |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20210000872A1 (ru) |
| EP (2) | EP4233883A3 (ru) |
| JP (1) | JP2021511079A (ru) |
| KR (1) | KR20200112915A (ru) |
| CN (1) | CN111886335A (ru) |
| AU (1) | AU2019213201A1 (ru) |
| BR (1) | BR112020014998A2 (ru) |
| CA (1) | CA3089294A1 (ru) |
| CL (1) | CL2020001943A1 (ru) |
| CO (1) | CO2020010266A2 (ru) |
| CR (1) | CR20200361A (ru) |
| EA (1) | EA202091753A1 (ru) |
| EC (1) | ECSP20050981A (ru) |
| ES (1) | ES2948969T3 (ru) |
| GB (1) | GB201801067D0 (ru) |
| IL (1) | IL276167A (ru) |
| MA (1) | MA51705A (ru) |
| MX (1) | MX2020007728A (ru) |
| PE (1) | PE20210843A1 (ru) |
| PH (1) | PH12020551110A1 (ru) |
| SG (1) | SG11202006875VA (ru) |
| WO (1) | WO2019145711A1 (ru) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
| GB201910605D0 (en) * | 2019-07-24 | 2019-09-04 | Immetacyte Ltd | Tumour infltracting lymphocyte therapy amd uses thereo |
| IL294098A (en) | 2019-12-20 | 2022-08-01 | Instil Bio Uk Ltd | Devices and methods for isolating lymphocytes infiltrating tumors and their use |
| CA3205464A1 (en) | 2020-12-18 | 2022-06-23 | Instil Bio (Uk) Limited | Processing of tumor infiltrating lymphocytes |
| EP4263807A2 (en) | 2020-12-18 | 2023-10-25 | Instil Bio (Uk) Limited | Processing of tumor infiltrating lymphocytes |
| WO2022130016A1 (en) | 2020-12-18 | 2022-06-23 | Instil Bio (Uk) Limited | Tumor infiltrating lymphocytes and anti-cd47 therapeutics |
| US20220313806A1 (en) | 2021-03-25 | 2022-10-06 | Iovance Biotherapeutics, Inc. | Methods and compositions for t-cell coculture potency assays and use with cell therapy products |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2386270A1 (en) | 1999-10-15 | 2001-04-26 | University Of Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| WO2001096584A2 (en) | 2000-06-12 | 2001-12-20 | Akkadix Corporation | Materials and methods for the control of nematodes |
| EP1777523A1 (en) | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
| SG11201508585PA (en) * | 2013-04-18 | 2015-11-27 | Tilt Biotherapeutics Oy | Enhanced adoptive cell therapy |
| CA2943389C (en) * | 2014-03-20 | 2023-10-31 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Tumor-infiltrating lymphocytes for adoptive cell therapy |
| WO2017179015A1 (en) * | 2016-04-15 | 2017-10-19 | Glaxosmithkline Intellectual Property Development Limited | Compositions for the treatment of cancer |
-
2018
- 2018-01-23 GB GBGB1801067.8A patent/GB201801067D0/en not_active Ceased
-
2019
- 2019-01-23 KR KR1020207024069A patent/KR20200112915A/ko not_active Application Discontinuation
- 2019-01-23 WO PCT/GB2019/050188 patent/WO2019145711A1/en unknown
- 2019-01-23 ES ES19702676T patent/ES2948969T3/es active Active
- 2019-01-23 CN CN201980020942.7A patent/CN111886335A/zh active Pending
- 2019-01-23 MX MX2020007728A patent/MX2020007728A/es unknown
- 2019-01-23 EP EP23177650.1A patent/EP4233883A3/en active Pending
- 2019-01-23 AU AU2019213201A patent/AU2019213201A1/en not_active Abandoned
- 2019-01-23 JP JP2020560612A patent/JP2021511079A/ja not_active Ceased
- 2019-01-23 MA MA051705A patent/MA51705A/fr unknown
- 2019-01-23 SG SG11202006875VA patent/SG11202006875VA/en unknown
- 2019-01-23 BR BR112020014998-5A patent/BR112020014998A2/pt unknown
- 2019-01-23 PE PE2020001006A patent/PE20210843A1/es unknown
- 2019-01-23 CA CA3089294A patent/CA3089294A1/en active Pending
- 2019-01-23 EP EP19702676.8A patent/EP3743511B1/en active Active
- 2019-01-23 CR CR20200361A patent/CR20200361A/es unknown
- 2019-01-23 EA EA202091753A patent/EA202091753A1/ru unknown
-
2020
- 2020-07-20 IL IL276167A patent/IL276167A/en unknown
- 2020-07-22 PH PH12020551110A patent/PH12020551110A1/en unknown
- 2020-07-22 US US16/935,612 patent/US20210000872A1/en not_active Abandoned
- 2020-07-23 CL CL2020001943A patent/CL2020001943A1/es unknown
- 2020-08-20 CO CONC2020/0010266A patent/CO2020010266A2/es unknown
- 2020-08-21 EC ECSENADI202050981A patent/ECSP20050981A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021511079A (ja) | 2021-05-06 |
| PH12020551110A1 (en) | 2021-07-05 |
| EP3743511B1 (en) | 2023-06-07 |
| US20210000872A1 (en) | 2021-01-07 |
| ES2948969T3 (es) | 2023-09-22 |
| AU2019213201A1 (en) | 2020-08-06 |
| IL276167A (en) | 2020-09-30 |
| CR20200361A (es) | 2021-01-13 |
| CL2020001943A1 (es) | 2021-02-26 |
| GB201801067D0 (en) | 2018-03-07 |
| SG11202006875VA (en) | 2020-08-28 |
| CN111886335A (zh) | 2020-11-03 |
| CA3089294A1 (en) | 2019-08-01 |
| EP3743511C0 (en) | 2023-06-07 |
| PE20210843A1 (es) | 2021-05-10 |
| MX2020007728A (es) | 2020-10-05 |
| WO2019145711A1 (en) | 2019-08-01 |
| EP4233883A2 (en) | 2023-08-30 |
| EP3743511A1 (en) | 2020-12-02 |
| MA51705A (fr) | 2020-12-02 |
| KR20200112915A (ko) | 2020-10-05 |
| CO2020010266A2 (es) | 2020-10-30 |
| BR112020014998A2 (pt) | 2020-12-29 |
| ECSP20050981A (es) | 2021-01-29 |
| EP4233883A3 (en) | 2023-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202091753A1 (ru) | Прогностический биомаркер терапии опухоль-инфильтрующими лимфоцитами и его применение | |
| Cluxton et al. | Differential regulation of human Treg and Th17 cells by fatty acid synthesis and glycolysis | |
| Ali et al. | Regulatory T cells in skin | |
| Lelis et al. | Myeloid-derived suppressor cells modulate B-cell responses | |
| Van Elssen et al. | Inflammation restraining effects of prostaglandin E2 on natural killer–dendritic cell (NK-DC) interaction are imprinted during DC maturation | |
| Braga et al. | The role of regulatory T cells and TH17 cells in multiple myeloma | |
| Yamanegi et al. | Sodium valproate, a histone deacetylase inhibitor, augments the expression of cell-surface NKG2D ligands, MICA/B, without increasing their soluble forms to enhance susceptibility of human osteosarcoma cells to NK cell-mediated cytotoxicity | |
| Chen et al. | Bone marrow-derived mesenchymal stem cells promote cell proliferation of multiple myeloma through inhibiting T cell immune responses via PD-1/PD-L1 pathway | |
| PH12021550307A1 (en) | T Cell Receptor Constructs And Uses Thereof | |
| Heffner et al. | Loss of T cell receptor-induced Bmi-1 in the KLRG1+ senescent CD8+ T lymphocyte | |
| MX2022000439A (es) | Terapia con linfocitos de infiltracion tumoral y sus usos. | |
| Bouillez et al. | MUC1-C promotes the suppressive immune microenvironment in non-small cell lung cancer | |
| Pola et al. | Vitronectin–αvβ3 integrin engagement directs hypoxia-resistant mTOR activity and sustained protein synthesis linked to invasion by breast cancer cells | |
| EA202092319A1 (ru) | Способы получения опухоль-инфильтрирующих лимфоцитов и применения их в иммунотерапии | |
| Yeo et al. | T‐bet‐mediated differentiation of the activated CD8+ T cell | |
| MA32948B1 (fr) | Anticorps anti-pd-l1 et leur utilisation pour ameliorer la fonction des lymphocytes t | |
| McCarthy et al. | Inosine pranobex enhances human NK cell cytotoxicity by inducing metabolic activation and NKG2D ligand expression | |
| Kemp et al. | Lck mediates Th2 differentiation through effects on T-bet and GATA-3 | |
| EA202090634A1 (ru) | Антагонисты tim-3 для лечения и диагностики онкологических заболеваний | |
| Wild et al. | Toll-like receptors in regulatory T cells of patients with head and neck cancer | |
| Ruppert et al. | Regulatory T cells resist cyclosporine-induced cell death via CD44-mediated signaling pathways | |
| Hillhouse et al. | Double-negative T cell levels correlate with chronic graft-versus-host disease severity | |
| Zhan et al. | Reduced inflammatory responses of follicular helper T cell promote the development of regulatory B cells after roux‐en‐Y gastric bypass | |
| Pedersen et al. | CD25 shedding by human natural occurring CD4+ CD25+ regulatory T cells does not inhibit the action of IL‐2 | |
| CN102698266A (zh) | Cd200在制备系统性红斑狼疮治疗药物中的应用 |